Shift in Diagnostic Paradigm from Invasive to Blood-Based Testing

The diagnosis of Alzheimer's disease is rapidly transitioning from invasive and costly methods, such as cerebrospinal fluid (CSF) collection and amyloid/tau positron emission tomography (PET), to blood-based diagnostics. CSF testing involves lumbar punctures, causing significant pain for patients, and PET scans are expensive, costing between $3,000 and $5,000 per scan, and have limited accessibility, hindering early diagnosis. The collaboration between Abbott Laboratories and ALZpath aims to overcome these limitations and popularize low-cost, high-precision blood tests, enabling early Alzheimer's screening in primary care settings. This is considered a significant turning point.

Global Standardization Competition for pTau217 Biomarker-Based Diagnostics

Through this agreement, Abbott will introduce ALZpath's core asset, the phosphorylated tau 217 (pTau217) antibody, and begin developing in-vitro diagnostic (IVD) reagents for its 'Alinity ci-series' immunoassay system. pTau217 is considered the most promising biomarker in the industry, as it can most sensitively and accurately detect amyloid plaque accumulation, a key pathological feature of Alzheimer's disease, in the blood. ALZpath, a non-listed biotech company, has created a strategic platform by combining its proprietary antibody technology with Abbott's large-scale global diagnostics infrastructure, further accelerating the technical standardization of the global diagnostics market.

Explosive Growth in Both the Therapeutic Market and Diagnostic Demand

The commercialization of blood-based early diagnostics is expected to be a critical factor in determining the market penetration of recently approved Alzheimer's therapeutics. To receive amyloid-targeting monoclonal antibody therapies, such as 'Leqembi' (generic: lecanemab), co-developed by Eisai and Biogen, and 'Kisunla' (generic: donanemab) from Eli Lilly, patients must first undergo testing to confirm the presence of amyloid deposits in the brain. As a result, the demand for affordable and high-throughput blood tests as a primary screening tool is rapidly increasing, replacing expensive PET scans. Abbott's entry is expected to serve as a catalyst for addressing this unmet medical need.

Major Diagnostic Companies Form Partnerships and Establish Dominant Positions

ALZpath has achieved a remarkable feat by securing pTau217 antibody license agreements with all four major global diagnostics companies: Roche, Beckman Coulter, Siemens Healthineers, and now Abbott. Siemens launched its research-use-only (RUO) reagent in March 2026, following its December 2025 agreement, and is proactively targeting the market. Roche and Beckman Coulter are also accelerating the development of diagnostic reagents for their large automated platforms. ALZpath's CEO, Mike Banville, emphasizes that this partnership with Abbott will solidify ALZpath's antibody technology as the dominant standard in the global in-vitro pTau217 diagnostics market, capturing approximately 80% of the market.